Global Partners L.P. (GLP)
NYSE NYSE Primary 
Should You Buy the Dip in Novo Nordisk Stock Right Now?
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chronic weight management, although research suggests these medications could have other applications in areas such as sleep apnea, kidney disease, and cardiovascular complications.
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. "This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here.
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
Viking Therapeutics: Holiday Gift
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment.
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs.
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide.
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and short-term subjects, completes a critical phase of the study.
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization ("CRO") to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda® injectable liraglutide. As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline.
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company.
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry
Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.
Millions more Americans might get access to GLP-1 drugs
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as investors tried to pick winners and losers in Donald Trump's tariff plans.
